文献速递糖尿病

2型糖尿病替代二线口服降糖治疗比较效果:应用于常规数据的精准医学方法

Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data.
PubMed 文献 · Diabetologia · 2025-05-31

该研究利用英格兰临床实践研究数据链(CPRD)2015—2021年41790例二甲双胍后起始二线治疗者的初级-医院链接数据,采用目标试验模拟联合工具变量分析比较磺脲类(SU)、DPP-4抑制剂(DPP4i)或SGLT-2抑制剂(SGLT2i)对HbA1c的影响。结果显示SGLT2i在降低HbA1c方面优于SU或DPP4i,且该优势在按年龄、基线HbA1c和多重长期疾病(MLTCs)划分的亚组中一致。

要点

  • SGLT2i较SU降低HbA1c的幅度在18-49岁组为-5.74 mmol/mol,大于50-69岁组(-4.03)和≥70岁组(-2.68)。
  • SGLT2i较DPP4i降低HbA1c的幅度在18-49岁组为-5.80 mmol/mol,在50-69岁组为-4.13,在≥70岁组为-3.13。
  • 无MLTC者SGLT2i较SU的HbA1c降幅为-5.37 mmol/mol,有MLTC者为-3.72 mmol/mol。

核心结论

  • SGLT2i作为二线治疗在降低HbA1c方面比SU或DPP4i更有效,且在年龄、基线HbA1c和MLTCs定义的亚组中一致。
  • 研究证据补充了随机对照试验,利用常规可获的人口学特征、生物标志物和合并症信息支持个体化治疗。

研究设计与样本

  • 利用英格兰临床实践研究数据链(CPRD)2015—2021年41790例二甲双胍后起始二线治疗者的初级-医院链接数据。
  • 采用目标试验模拟联合工具变量分析以减少混杂风险,结局为基线与1年随访间HbA1c变化。

主要发现

  • SGLT2i vs SU的HbA1c变化平均差(95%CI)在18-49岁组为-5.74 mmol/mol(-7.47, -4.01)(-0.5% [-0.7, -0.4]),50-69岁组为-4.03 mmol/mol(-5.61, -2.44)(-0.4% [-0.5, -0.2]),≥70岁组为-2.68 mmol/mol(-4.50, -0.86)(-0.3% [-0.4, -0.07])。
  • SGLT2i vs DPP4i的HbA1c变化平均差(95%CI)在18-49岁组为-5.80 mmol/mol(-7.60, -4.00)(-0.5% [-0.7, -0.4]),50-69岁组为-4.13 mmol/mol(-5.82, -2.45)(-0.4% [-0.5, -0.2]),≥70岁组为-3.13 mmol/mol(-5.01, -1.24)(-0.3% [-0.4, -0.1])。
  • 按基线HbA1c或MLTCs定义的亚组间HbA1c平均改善相似。
  • SGLT2i vs SU的HbA1c平均差(95%CI)在无MLTC者为-5.37 mmol/mol(-7.13, -3.62)(-0.5% [-0.6, -0.3]),有MLTC者为-3.72 mmol/mol(-5.34, -2.10)(-0.3% [-0.5, -0.2])。
  • SGLT2i vs DPP4i的对应估计差(95%CI)在无MLTC者为-5.44 mmol/mol(-7.27, -3.61)(-0.5% [-0.7, -0.3]),有MLTC者为-3.93 mmol/mol(-5.64, -2.21)(-0.3% [-0.5, -0.2])。

关键数值与推荐

  • 年龄分层:18-49岁、50-69岁、≥70岁。
  • 基线HbA1c分层:<67 mmol/mol(<8.3%)、67-77 mmol/mol(8.3-9.2%)、>77 mmol/mol(>9.2%)。
  • 按是否存在MLTCs分层。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: National clinical guidelines recommend that second-line treatment for type 2 diabetes mellitus is chosen according to individuals' characteristics but there is limited evidence available to inform this choice. This paper's aim is to compare the effects on HbA1c of sulfonylureas (SU), dipeptidyl peptidase-4 inhibitors (DPP4i) or sodium-glucose cotransporter-2 inhibitors (SGLT2i) added to metformin as second-line oral glucose-lowering treatments according to an individual's age, baseline HbA1c and presence of multiple long-term conditions (MLTCs). METHODS: We accessed primary care-hospital linked data for 41,790 individuals from the Clinical Practice Research Datalink (CPRD) in England who initiated second-line treatment after metformin between 2015 and 2021. We combined target trial emulation with instrumental variable analysis to reduce the risk of confounding. The outcome was change in HbA1c between baseline and 1 year follow-up. We reported results stratified by age (18-49 years, 50-69 years and ≥70 years), baseline HbA1c (<67 mmol/mol [<8.3%], 67-77 mmol/mol [8.3-9.2%] and >77 mmol/mol [>9.2%]) and presence of MLTCs. RESULTS: The mean (95% CI) difference in HbA1c change for SGLT2i vs SU was larger for people aged 18-49 years (-5.74 mmol/mol [-7.47, -4.01]) (-0.5% [-0.7, -0.4]) than for those aged 50-69 years (-4.03 mmol/mol [-5.61, -2.44]) (-0.4% [-0.5, -0.2]) and for those aged 70 years or over (-2.68 mmol/mol [-4.50, -0.86]) (-0.3% [-0.4, -0.07]). The mean (95% CI) difference in HbA1c change for SGLT2i vs DPP4i was -5.80 mmol/mol (-7.60, -4.00) (-0.5% [-0.7, -0.4]) for those aged 18-49 years, -4.13 mmol/mol (-5.82, -2.45) (-0.4% [-0.5, -0.2]) for those aged 50-69 years and -3.13 mmol/mol (-5.01, -1.24) (-0.3% [-0.4, -0.1]) for those aged ≥70 years. The mean difference (improvement) in HbA1c was similar across subgroups defined by baseline HbA1c or presence of MLTCs. For SGLT2i vs SU, the mean (95% CI) difference was -5.37 mmol/mol (-7.13, -3.62) (-0.5% [-0.6, -0.3]) for people without MLTC and -3.72 mmol/mol (-5.34, -2.10]) (-0.3% [-0.5, -0.2]) for people with MLTC. For SGLT2i vs DPP4i the corresponding estimated differences (95% CI) were -5.44 mmol/mol (-7.27, -3.61) (-0.5% [-0.7, -0.3]) for those without MLTC and -3.93 mmol/mol (-5.64, -2.21) (-0.3% [-0.5, -0.2]) for those with MLTC. CONCLUSIONS/INTERPRETATION: Second-line treatment with SGLT2i is more effective than SU or DPP4i in reducing HbA1c across subgroups of people defined by age, baseline HbA1c and presence of MLTCs. Our evidence complements RCTs in using routinely available information on demographic characteristics, biomarkers and comorbidities to inform an individualised approach.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. O'Neill S, Bidulka P, Lugo-Palacios DG, et al. Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data. Diabetologia. 2025. PMID: 40450157. doi:10.1007/s00125-025-06447-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。